Affluent Medical to Transform Cardiovascular Therapies with Carvolix Formation

Affluent Medical announced plans to acquire Caranx Medical and Artedrone, forming Carvolix, a new entity focused on cardiovascular therapies using AI-driven mini-robots and innovative implants. This strategic move, involving a cashless transaction, integrates advanced robotic, AI, and implant technologies aimed at revolutionizing cardiac valve replacement and stroke care.

The market for these therapies is projected to reach $23 billion by 2030. Financing up to €30 million, secured with support from Truffle Capital and Edwards Lifesciences, will support the development and commercialization of Carvolix's offerings, including the FDA-cleared TAVIPILOT software for aortic valve replacement.

The transaction is set to finalize by January 2026, with a general meeting scheduled for January 30, 2026. The company aims to enhance the capabilities of interventional cardiology, making advanced procedures more accessible globally.